SCHEMBL22489134

SCHEMBL22489134

O=C(Nc1cc(-c2nc3ccccc3[nH]2)n[nH]1)c1ccc(O)c(O)c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FOXO1 Q12778 7/20 0.58
▸ CHEK1 O14757 4/20 0.52
▸ ADORA2A P29274 1/20 0.51
▸ CDK1 P06493 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ THRB P10828 1/20 0.49
▸ RECQL P46063 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ ATM Q13315 1/20 0.49
▸ HPSE Q9Y251 1/20 0.49
▸ ALPL P05186 2/20 0.48
▸ ALPG P10696 2/20 0.48
▸ PLAA Q9Y263 1/20 0.48
▸ TOP1 P11387 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22488757 0.92 FOXO1 (0.70) FOXO1CHEK1ADORA2ACDK1KDM4E
SCHEMBL22489138 0.88 FOXO1 (0.58) FOXO1CHEK1NPC1POLBRAB9A
SCHEMBL22489011 0.88 MMP2 (0.59) FOXO1ADORA2ACDK1KDM4EMEN1
SCHEMBL22488979 0.87 NPC1 (0.61) FOXO1KDM4EMEN1NPC1POLB
SCHEMBL24513591 0.86 NPC1 (0.60) FOXO1CHEK1CDK1KDM4EMEN1
SCHEMBL22488747 0.86 ADORA2A (0.60) FOXO1CHEK1ADORA2ACDK1KDM4E
SCHEMBL22488976 0.86 NPC1 (0.60) FOXO1CDK1KDM4EMEN1NPC1
SCHEMBL22488975 0.85 NPC1 (0.65) FOXO1CDK1KDM4EMEN1NPC1
SCHEMBL22488981 0.84 NPC1 (0.64) FOXO1CDK1KDM4EMEN1NPC1
SCHEMBL22488995 0.84 FOXO1 (0.68) FOXO1KDM4EMEN1NPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220185797-A1 SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2022-06-16 — — US disclosed
WO-2020198351-A1 SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-10-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220185797-A1 SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION FOXO1, FOXO3, FOXK1 FOXO1 1/4885CHEK1 1693/4885ADORA2A 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback